Heart Failure | Unmet Need | Chronic Heart Failure | US/FR/DE/UK | 2021
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure (CHF) cases, but proven pharmacological treatment options are limited. In February 2021, the FDA approved Entresto, an angiotensin receptor-neprilysin inhibitor (ARNI) marketed by Novartis for HFpEF, making it the first approved therapy for this subpopulation. Despite a long list of clinical trial failures, the HFpEF pipeline has some promising candidates, such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors and mineralocorticoid receptor antagonists (MRAs). Substantial market opportunity remains for effective therapies to treat this heterogeneous and highly prevalent population.
QUESTIONS ANSWERED
- Which drug attributes are the most influential in driving cardiologists’ prescribing decisions?
- Which therapies used in the treatment of HFpEF do cardiologists perceive as performing the best on efficacy, safety and tolerability, and convenience of administration attributes?
- What are the major areas of opportunity for drug developers in HFpEF treatment, and what is their likelihood of being fulfilled in the near future?
- What are the trade-offs that surveyed cardiologists are willing to make across key attributes when considering new treatments for HFpEF?
PRODUCT DESCRIPTION
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European cardiologists fielded in March 2021.
Key companies: Novartis, Pfizer
Key drugs: ACE inhibitors, ARBs, ARNIs (Entresto, sacubitril / valsartan), beta blockers, calcium channel blockers, diuretics, MRAs
